This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL (NCT02557516), a non-randomized phase 1, phase 2 study. The primary outcome is Number of Dose Limiting Toxicities.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT02557516 |
| Phase | Phase 1, Phase 2 |
| Condition | Chronic Lymphocytic Leukemia |
| Allocation | Non-Randomized |
| Design model | Sequential |
| Masking | None (open label) |
| Enrollment | 22 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Innate Pharma |
| Results posted | Yes |
2. Clinical Question
Population
Patients with chronic lymphocytic leukemia who had relapsed disease, refractory disease, or had not previously been treated. The registry record does not report further eligibility details or characteristics of the people enrolled.
Intervention
Monalizumab (IPH2201) in combination with ibrutinib. In phase 1, the study assessed monalizumab at dose levels of 1 mg/kg, 2 mg/kg, and 4 mg/kg. In phase 2, the listed dose was 2 mg/kg, described as the recommended phase 2 dose selected by a safety committee.
Comparator
There was no randomized control group. The study was non-randomized and sequential, with dose levels rather than a like-for-like control comparison. Differences across dose groups cannot be interpreted as randomized treatment effects.
Primary question
During the phase 1 dose-escalation part, how many dose-limiting toxicities were observed during the 8 weeks used for the primary endpoint? The registry record describes the endpoint and safety-evaluated population, but does not report the dose-limiting toxicity count.
The study was designed in two parts. The registry summary describes phase 1 as a 3+3 design to assess the maximum tolerated dose and phase 2 as an evaluation of the combination's anti-leukemic activity. These descriptions identify the study aims; they do not establish what was observed. In particular, the available record does not give a primary endpoint result, a maximum tolerated dose result, or an estimate of anti-leukemic activity.
The listed secondary outcomes are best overall response or remission rates, duration of remission, progression-free survival, and overall survival. Results for those outcomes are not reported in the registry record. The clinical question therefore has a clear treatment and disease context, but its answer cannot be reconstructed from the endpoint definition or the dose-group descriptions alone.
3. Trial Design
This was an open-label phase 1/2 study of monalizumab with ibrutinib in chronic lymphocytic leukemia. The registry lists the study as non-randomized, unmasked, and sequential. Enrollment was 22. The study started on 2015-11-09, its primary completion date was 2018-10-29, and its status is terminated. The reason for termination is not reported in the registry record.
The design had two parts. In phase 1, dose escalation was described as using a 3+3 design to assess the maximum tolerated dose. The primary endpoint was the number of dose-limiting toxicities during an 8-week timeframe. The record states that 13 patients were evaluated for safety during phase 1: 3 received at least one dose of monalizumab 1 mg/kg, 6 received 2 mg/kg, and 4 received 4 mg/kg. The dose groups were not assigned through randomization.
In phase 2, the stated aim was to evaluate anti-leukemic activity. The listed phase 2 dose was 2 mg/kg, described as the recommended phase 2 dose selected by a safety committee. The registry lists response or remission, duration of remission, progression-free survival, and overall survival as secondary outcomes. It does not report the phase 2 analysis population or results for these outcomes.
Because the study was sequential and had no randomized comparator, comparisons between dose groups are not equivalent to comparisons between groups assigned to different treatments under randomization. Groups may differ for reasons related to the design, including their place in the dose-escalation sequence. The registry record does not report allocation details beyond the non-randomized sequential design, nor does it describe the criteria used by the safety committee to select the phase 2 dose.
The record lists 22 enrolled participants overall, while the primary endpoint description identifies 13 phase 1 participants evaluated for safety. Those are distinct descriptions of enrollment and the phase 1 safety population. The record does not provide a fuller accounting of participants by study part, treatment exposure, follow-up, or analysis population. It also does not report a protocol-level statistical analysis plan or the reason the study was terminated.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: The first part of the study had a 3+3 design. Four dose levels of monalizumab were planned: 1 mg/kg, 2 mg/kg, 4 mg/kg and 10 mg/kg. Dose-escalation decisions were made by a Safety Committee.The dose of monalizumab for all patients in phase 2 of the study (2 mg/kg) was also chosen by the Safety Committee based on phase 1 data.
Overall Study
| Stage | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg |
|---|---|---|---|---|
| STARTED | 3 | 6 | 4 | 9 |
| COMPLETED | 2 | 1 | 0 | 0 |
| NOT COMPLETED | 1 | 5 | 4 | 9 |
Reasons for not completing this period:
| Reason | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg |
|---|---|---|---|---|
| Adverse Event | 1 | 0 | 2 | 1 |
| Disease progression | 0 | 2 | 0 | 0 |
| Physician Decision | 0 | 2 | 0 | 0 |
| Sponsor decision | 0 | 1 | 2 | 8 |
Analysis population for the primary outcome, as defined in the registry: During phase 1 part of the study (dose escalation) the total number of patients evaluated for safety parameters is 13; 3 patients received at least one dose of monalizumab 1 mg/kg, 6 patients received 2 mg/kg , and 4 patients received 4 mg/kg.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg | Total |
|---|---|---|---|---|---|---|
| Participants analysed | 3 | 6 | 4 | 9 | 22 | |
| Age, Continuous | years | 59.3 (SD 11.15) | 65.8 (SD 7.14) | 69.5 (SD 10.08) | 69.4 (SD 6.33) | 67.1 (SD 8.14) |
| Sex: Female, Male: Female | Participants | 0 | 3 | 3 | 2 | 8 |
| Sex: Female, Male: Male | Participants | 3 | 3 | 1 | 7 | 14 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 3 | 6 | 4 | 9 | 22 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Asian | Participants | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Black or African American | Participants | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB): White | Participants | 3 | 6 | 4 | 7 | 20 |
| Race (NIH/OMB): More than one race | Participants | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment: United States | participants | 3 | 6 | 4 | 9 | 22 |
| ECOG Performance Status: ECOG 0 | Participants | 3 | 2 | 0 | 7 | 12 |
| ECOG Performance Status: ECOG 1 | Participants | 0 | 4 | 4 | 2 | 10 |
| RAI Stage: Stage I | Participants | 0 | 0 | 0 | 3 | 3 |
| RAI Stage: Stage II | Participants | 2 | 1 | 0 | 0 | 3 |
| RAI Stage: Stage III | Participants | 0 | 1 | 1 | 0 | 2 |
| RAI Stage: Stage IV | Participants | 1 | 4 | 3 | 6 | 14 |
| Disease Status at Screening: Previously Untreated CLL | Participants | 0 | 1 | 0 | 6 | 7 |
| Disease Status at Screening: Refractory CLL | Participants | 0 | 1 | 1 | 0 | 2 |
| Disease Status at Screening: Relapse CLL | Participants | 3 | 4 | 3 | 3 | 13 |
6. Primary Endpoint
The registry lists the primary outcome as Number of Dose Limiting Toxicities, measured over 8 weeks.
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | not applicable |
| Unit | Dose Limiting Toxicy |
| Endpoint classification | not reduced to a single comparison |
The primary endpoint is the number of dose-limiting toxicities during the phase 1 dose-escalation part of the study, with an 8-week timeframe. A dose-limiting toxicity is used in dose-escalation research to identify safety events that constrain the doses that can be considered for further study. Counting such events can inform dose selection alongside clinical judgment and the study's safety procedures. The registry record does not provide a definition of which events qualified as dose-limiting toxicities, how severity was classified, or how attribution to treatment was determined.
This endpoint is a count, rather than a comparison of response rates or a time-to-event outcome. Its interpretation depends on the number of participants assessed at each dose and on consistent event ascertainment during the stated timeframe. The registry describes 13 phase 1 participants evaluated for safety, distributed across the 1 mg/kg, 2 mg/kg, and 4 mg/kg dose levels. It does not report the number of dose-limiting toxicities observed, either overall or by dose level. The endpoint result is therefore not reported in the registry record.
The dose-limiting toxicity endpoint is specific to phase 1 and should not be confused with the listed secondary outcomes, which concern response, remission, progression-free survival, and overall survival. The registry's endpoint description alone does not establish tolerability, efficacy, or the dose selected for phase 2. It identifies what was intended to be measured, not what the measurement found.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The record supports a description of the study's structure and some safety-population details, but it does not report the primary endpoint result. Although the primary outcome is named as the number of dose-limiting toxicities, no count is given. The phase 1 safety population is described as 13 participants, with 3 at 1 mg/kg, 6 at 2 mg/kg, and 4 at 4 mg/kg. Those group sizes do not reveal how many dose-limiting toxicities occurred. It would be incorrect to infer a count from the dose levels, the safety committee's selection of a phase 2 dose, or the adverse-event summaries.
The study's overall enrollment was 22, while the primary endpoint population refers to 13 phase 1 participants evaluated for safety. The record does not explain the distribution of the remaining enrolled participants across phases or analysis sets. This difference in scope means that enrollment should not be treated as the denominator for the phase 1 primary endpoint.
The adverse-event listing reports serious-event and other-event counts for groups labeled 1 mg/kg, 2 mg/kg, and 4 mg/kg, as well as deaths. These figures describe the listed safety data, not the primary endpoint count. In particular, the number of participants with serious adverse events cannot be substituted for the number with dose-limiting toxicities: the concepts and definitions need not be the same, and the record does not identify which events were dose-limiting. The adverse-event population descriptions also differ from the phase 1 safety group sizes, including the listing of 15 people at risk in the 2 mg/kg group. The record does not explain the relationship between these populations, so the figures should be read in their reported context rather than combined.
No clinical outcome estimates or analysis results are reported in the registry record. Best overall response or remission rates, duration of remission, progression-free survival, and overall survival are named as secondary outcomes, but there are no reported estimates, confidence intervals, or tests for them. The record therefore cannot establish the size or precision of any treatment-associated change in those outcomes.
The study was non-randomized, sequential, and open-label. Consequently, any descriptive differences across dose groups would not by themselves isolate a causal effect of dose or treatment. There is no randomized control comparison to distinguish treatment effects from differences in participants, timing, follow-up, or other factors. The registry does not report an analysis plan, adjustment strategy, or additional details that would resolve these interpretive limits.
The sample-size material is described as a planning illustration based on an observed effect, with two-sided significance level 0.05, equal allocation, and a normal approximation. Such calculations are hypothetical planning aids, not observed power and not evidence that the trial was designed or powered according to those assumptions. The registry record does not report the study's own sample-size justification. Without reported outcome estimates and analysis results, the planning calculations cannot fill the gap in evidence about what the study observed.
9. Statistical Methods Explained
Statistical methods help distinguish what a study intended to measure from what its results can support. In this study, the registry identifies a dose-escalation safety endpoint and several secondary clinical outcomes, but does not report outcome analyses. The concepts below explain how such methods are generally interpreted; they do not describe an analysis plan that is not reported in the registry record.
What does a count endpoint represent?
The primary endpoint is a count of dose-limiting toxicities during an 8-week timeframe in phase 1. A count records how many events meet a specified definition in the population being assessed. To interpret it, readers need the event definition, the population at risk, the observation window, and the rules used to determine whether an event qualifies. The registry gives the timeframe and describes the safety-evaluated population, but does not report the event count or the detailed event definition. Thus, the intended measure is identifiable, while its observed value and operational details are not.
Counts can be presented as totals, or analyzed with statistical models suited to event-count data. The appropriate approach depends on the distribution of events and how observation time and participant exposure are handled. Some count data show over-dispersion, meaning that variability exceeds what a simple model would expect. In general, failing to account for over-dispersion can make uncertainty appear too small. The registry record does not report a count model, an over-dispersion assessment, or any model-based result for the primary endpoint.
Why does the dose-escalation structure matter?
A 3+3 dose-escalation design is a rule-based approach for making decisions about dose levels as participants are treated in sequence. The registry describes phase 1 as using this design to assess the maximum tolerated dose, but it does not report the specific decision rules, observed toxicities by dose, or the resulting maximum tolerated dose. The general design description should not be mistaken for evidence that a particular dose was found tolerable or that a maximum tolerated dose was established.
Sequential dose assignment also affects how groups can be compared. Participants at different dose levels are not necessarily exchangeable: dose level is connected to the order of study decisions, and later cohorts may differ from earlier ones. Randomization is not listed. Therefore, any apparent variation across dose groups would be descriptive unless a suitable analysis and assumptions supported a stronger interpretation. No such comparative analysis is reported in the registry record.
How should estimates and confidence intervals be read?
In general, an estimate summarizes the observed result for a population or contrast, while a confidence interval expresses uncertainty around that estimate under the statistical method used. A wider interval indicates less precision; a narrower interval indicates greater precision, conditional on the model and data. A confidence interval does not establish that an effect is clinically important, and a result outside a conventional threshold does not by itself establish a causal effect. No primary endpoint estimate or confidence interval is reported in the registry record, and no confidence intervals for secondary outcomes are reported.
When outcome results are absent, precision cannot be evaluated. The group sizes alone do not provide an estimate or its uncertainty. Nor do they allow a reader to reconstruct an event count or a response estimate without inventing information. This is why the phase 1 safety population description can be reported, but cannot stand in for the missing dose-limiting toxicity result.
What do the planning calculations mean?
In general, sample-size calculations describe how much information a hypothetical study might need under specified assumptions. The planning illustration described for this study uses a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect defined as a stated fraction of an observed effect. For time-to-event outcomes, it describes total events; for other outcomes, it describes participants per arm. These are planning assumptions, not a record of the trial's actual design or a measure of observed power. The registry record does not report the study's own sample-size justification.
A planning calculation is sensitive to its assumed effect, variability, event frequency, analysis method, and allocation. If the observed effect used as an input is uncertain, calculations built from it inherit that uncertainty. Planning illustrations can help show how sample size depends on assumptions, but cannot establish that an enrolled study had adequate precision or that a result is reliable. The registry information available for this study does not include outcome estimates needed to judge the observed effect or its uncertainty.
What can be inferred from absent analyses?
The registry lists six outcome measures and reports zero analyses. In general, an outcome listed in a registry is not the same as an outcome result. An analysis would usually identify the population analyzed, the statistical summary or model, and an estimate of uncertainty where applicable. Without reported analyses, readers cannot assess missing observations, follow-up, censoring, model assumptions, or whether analyses followed a prespecified plan.
The absence of analysis results does not establish that an outcome was favorable, unfavorable, or unchanged. It means that the registry record does not report a result that can be interpreted statistically. For this trial, the endpoint descriptions and safety counts provide limited context about what was measured, but they do not substitute for the absent endpoint and secondary-outcome analyses.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists six outcome measures, including the primary count of dose-limiting toxicities and secondary outcomes concerning response or remission, duration of remission, progression-free survival, and overall survival. It reports zero analyses. There are therefore no reported statistical tests or outcome estimates from which to determine whether any multiplicity procedure was used.
In general, multiplicity arises when several outcomes, comparisons, time points, or analyses are examined. Testing many hypotheses can increase the chance of at least one apparently notable result by chance. Statistical plans may address this through prespecified outcome hierarchies, adjusted significance thresholds, or other methods. The registry record does not report whether any such approach was planned or applied. It also does not report an analysis plan describing which outcomes were primary for inference, how secondary outcomes were to be interpreted, or whether interim analyses were planned.
The record does not describe missing-data methods, the amount of missing outcome data, follow-up completeness, censoring rules, or sensitivity analyses. Those details matter because incomplete observation can affect estimates, especially for time-to-event outcomes such as progression-free survival and overall survival. Without an analysis population and a description of how missingness or censoring was handled, the precision and potential biases of outcome estimates cannot be evaluated.
The registry identifies 22 enrolled participants overall and 13 phase 1 participants evaluated for safety, but does not provide participant flow or outcome-specific denominators. It does not state whether analyses used all enrolled participants, treated participants, participants with evaluable outcomes, or another population. The absence of these details limits interpretation independently of any statistical method that might have been used.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| 1 mg/kg | 2 | 3 | 66.7% |
| 2 mg/kg | 5 | 15 | 33.3% |
| 4 mg/kg | 3 | 4 | 75.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| 1 mg/kg | 0 of 3 |
| 2 mg/kg | 0 of 15 |
| 4 mg/kg | 0 of 4 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 0% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| 1 mg/kg | 3 of 3 |
| 2 mg/kg | 15 of 15 |
| 4 mg/kg | 4 of 4 |
Most frequent serious adverse event terms
| Event term | Organ system | 1 mg/kg | 2 mg/kg | 4 mg/kg |
|---|---|---|---|---|
| Supraventricular tachycardia | Cardiac disorders | 1 of 3 | 0 of 15 | 0 of 4 |
| Large intestinal haemorrhage | Gastrointestinal disorders | 0 of 3 | 0 of 15 | 1 of 4 |
| Lower gastrointestinal haemorrhage | Gastrointestinal disorders | 0 of 3 | 1 of 15 | 0 of 4 |
| Pyrexia | General disorders | 0 of 3 | 0 of 15 | 1 of 4 |
| Sinusitis | Infections and infestations | 0 of 3 | 1 of 15 | 0 of 4 |
| Urinary tract infection enterococcal | Infections and infestations | 0 of 3 | 1 of 15 | 0 of 4 |
| Urosepsis | Infections and infestations | 1 of 3 | 0 of 15 | 0 of 4 |
| Amylase increased | Investigations | 0 of 3 | 0 of 15 | 1 of 4 |
| Platelet count decreased | Investigations | 0 of 3 | 1 of 15 | 0 of 4 |
| Bladder cancer recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0 of 3 | 1 of 15 | 0 of 4 |
Most frequent non-serious adverse event terms
| Event term | Organ system | 1 mg/kg | 2 mg/kg | 4 mg/kg |
|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | 2 of 3 | 9 of 15 | 4 of 4 |
| Contusion | Injury, poisoning and procedural complications | 3 of 3 | 8 of 15 | 0 of 4 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 1 of 3 | 8 of 15 | 2 of 4 |
| Cough | Respiratory, thoracic and mediastinal disorders | 1 of 3 | 8 of 15 | 2 of 4 |
| Myalgia | Musculoskeletal and connective tissue disorders | 2 of 3 | 7 of 15 | 1 of 4 |
| Hypertension | Vascular disorders | 1 of 3 | 7 of 15 | 2 of 4 |
| Stomatitis | Gastrointestinal disorders | 0 of 3 | 6 of 15 | 2 of 4 |
| Upper respiratory tract infection | Infections and infestations | 1 of 3 | 5 of 15 | 1 of 4 |
| Decreased appetite | Metabolism and nutrition disorders | 2 of 3 | 5 of 15 | 0 of 4 |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | 2 of 3 | 5 of 15 | 0 of 4 |
Serious events with the highest arm-level rate: supraventricular tachycardia (33.3%), urosepsis (33.3%), myelodysplastic syndrome (33.3%), large intestinal haemorrhage (25.0%), pyrexia (25.0%).
The registry lists serious adverse events, other adverse events, and deaths for dose groups labeled 1 mg/kg, 2 mg/kg, and 4 mg/kg. For serious adverse events, it reports 2 of 3 at risk in the 1 mg/kg group, 5 of 15 in the 2 mg/kg group, and 3 of 4 in the 4 mg/kg group. For other adverse events, it reports 3 of 3, 15 of 15, and 4 of 4, respectively. Deaths are listed as 0 in each group. These are descriptive safety figures as recorded, not estimates from a randomized comparison.
The listed serious-event terms include Supraventricular tachycardia, Urosepsis, and Myelodysplastic syndrome at 33.3% each, and Large intestinal haemorrhage, Pyrexia, and Amylase increased at 25.0% each. The record does not provide the counts or denominator definitions underlying those term percentages, so they should not be used to infer additional event totals.
The safety group sizes do not match the phase 1 dose-escalation group sizes described for the primary endpoint: the phase 1 safety description gives 3, 6, and 4 participants, while the adverse-event listing identifies 3, 15, and 4 at risk. The registry record does not explain this difference or define how these safety populations relate. Serious adverse events also are not interchangeable with dose-limiting toxicities. The record does not identify which serious events, if any, met the primary endpoint definition.
12. What the Result Does, and Does Not, Mean
The registry record establishes that a non-randomized, open-label, sequential phase 1/2 study of monalizumab with ibrutinib was conducted in chronic lymphocytic leukemia and was later listed as terminated. It describes a phase 1 dose-escalation aim, a phase 2 anti-leukemic activity aim, the primary safety endpoint, and several secondary outcomes. It also gives enrollment and safety-population information and lists adverse-event figures.
Those details do not provide the study's primary endpoint result. The number of dose-limiting toxicities is not reported in the registry record. Nor are results reported for response or remission, duration of remission, progression-free survival, or overall survival. Consequently, the record does not support a quantitative conclusion about the observed anti-leukemic activity or about the precision of any clinical outcome estimate. The listed adverse-event counts describe safety observations, but cannot be used to reconstruct the missing primary endpoint result.
The design also limits what comparisons could mean. Dose groups were not randomized, and the study had no like-for-like control group. Differences between dose groups, even if outcome results were available, would not by themselves separate a dose effect from other differences associated with the sequential design. The registry does not report adjustment methods or analyses that might address such concerns.
The planning illustrations are not observed-power calculations and do not show how precise the study's results were. They reflect stated assumptions for hypothetical planning. The record does not report the trial's own sample-size justification or the analyses needed to evaluate outcome uncertainty.
Accordingly, the most defensible interpretation is limited: the record documents the study's intended questions, design features, participant counts in specified contexts, and selected safety summaries. It does not report enough outcome information to determine what the primary endpoint or secondary outcomes showed. The absence of results in the registry record should not be interpreted as evidence of a particular treatment effect or as evidence that no events occurred.
13. Why This Trial Matters Statistically
This study illustrates why registry design details and outcome reporting need to be read separately. A registry may identify a primary endpoint and describe who was evaluated, yet still provide no endpoint result. Here, the phase 1 objective and dose groups are described, but the dose-limiting toxicity count is not reported. The distinction matters: knowing the intended measure and its timeframe does not reveal the observation.
The record also illustrates the interpretive limits of sequential, non-randomized dose groups. Dose escalation is designed to inform decisions about dose, but it does not create randomized groups suitable for a direct treatment comparison. Reading dose-group summaries as though they were controlled comparisons would overstate what the design can establish.
Safety reporting further shows why populations and endpoints must be kept distinct. The phase 1 endpoint description identifies safety evaluation among 13 participants, while the adverse-event listing gives different at-risk group counts for some dose levels. The registry does not explain that difference. Serious adverse events, other adverse events, and dose-limiting toxicities are also distinct measures; one cannot be substituted for another without definitions and participant-level or analysis information.
Finally, the registry lists several clinically relevant secondary outcomes but reports no analyses. This makes the record useful for understanding the planned scope and the limitations of the available evidence, while leaving the study's outcome findings unresolved. Statistical interpretation depends not only on the choice of method, but on transparent reporting of the analyzed population, observed results, and uncertainty.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The most consequential limitation is that the registry does not report a result for the primary endpoint. It names the number of dose-limiting toxicities and an 8-week timeframe, but provides no count, dose-specific result, or uncertainty estimate. The operational definition of a dose-limiting toxicity and the rules for attribution are also not reported in the registry record.
The study is listed as terminated, but the reason for termination is not reported. The record does not describe whether termination affected recruitment, treatment exposure, follow-up, or outcome ascertainment. It also does not provide a participant-flow account connecting the overall enrollment of 22 with the 13 participants evaluated for phase 1 safety and the adverse-event populations.
Safety summaries have a population-detail limitation: the adverse-event listing reports 15 at risk in the 2 mg/kg group, whereas the phase 1 dose-escalation description reports 6 participants who received 2 mg/kg. The registry record does not explain how those figures relate, so they should not be reconciled by assumption. Event-term percentages are listed without counts or denominator definitions.
The non-randomized, sequential, open-label design has no randomized control comparison. This limits causal interpretation and makes dose-group contrasts vulnerable to differences associated with sequence and participant composition. The record does not report details of dose-assignment decisions, the safety committee's selection criteria, or analyses designed to address such differences.
Analysis details are also absent. The record does not report a statistical analysis plan, outcome-specific analysis populations, missing-data handling, censoring rules, multiplicity procedures, interim analyses, or the study's own sample-size justification. It lists secondary outcomes but reports no analyses or results for them. These gaps prevent assessment of outcome precision, robustness, and completeness.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL — NCT02557516.
- Registry record last updated 2019-12-17; status last verified 2019-12.
- Results first posted 2019-12-17.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
The registry record describes an open-label, non-randomized, sequential phase 1/2 study of monalizumab with ibrutinib in chronic lymphocytic leukemia. It lists 22 enrolled participants and a terminated status. Phase 1 was described as dose escalation using a 3+3 design, with monalizumab dose levels of 1 mg/kg, 2 mg/kg, and 4 mg/kg. The primary endpoint was the number of dose-limiting toxicities during an 8-week timeframe; 13 participants were described as evaluated for phase 1 safety.
Phase 2 was intended to evaluate anti-leukemic activity, with 2 mg/kg listed as the recommended phase 2 dose selected by a safety committee. Secondary outcomes included response or remission, duration of remission, progression-free survival, and overall survival. The registry lists safety-event figures, but does not report the primary endpoint result or analyses of the listed clinical outcomes. The reason for termination, the study's statistical analysis plan, and its sample-size justification are not reported in the registry record.